Business Description
InMed Pharmaceuticals Inc
NAICS : 325410
SIC : 3741
ISIN : CA4576371062
Total Employee Number:
13Description
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12.28 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -18.4 | |||||
Beneish M-Score | -3.4 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -49.3 | |||||
3-Year EBITDA Growth Rate | 75 | |||||
3-Year EPS without NRI Growth Rate | 74.3 | |||||
3-Year FCF Growth Rate | 75.7 | |||||
3-Year Book Growth Rate | -71 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.69 | |||||
9-Day RSI | 44.1 | |||||
14-Day RSI | 45.43 | |||||
3-1 Month Momentum % | -1.2 | |||||
6-1 Month Momentum % | 92.94 | |||||
12-1 Month Momentum % | -27.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.12 | |||||
Quick Ratio | 3.12 | |||||
Cash Ratio | 2.33 | |||||
Days Inventory | 254.5 | |||||
Days Sales Outstanding | 17.2 | |||||
Days Payable | 91.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -292.9 | |||||
Shareholder Yield % | -44.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.34 | |||||
Operating Margin % | -117.12 | |||||
Net Margin % | -123.62 | |||||
EBITDA Margin % | -105.91 | |||||
FCF Margin % | -108.35 | |||||
OCF Margin % | -108.35 | |||||
ROE % | -87.67 | |||||
ROA % | -72.67 | |||||
ROIC % | -223.63 | |||||
3-Year ROIIC % | -2996.94 | |||||
ROC (Joel Greenblatt) % | -634.88 | |||||
ROCE % | -79.3 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.47 | |||||
PB Ratio | 0.68 | |||||
Price-to-Tangible-Book | 0.87 | |||||
EV-to-EBIT | -0.35 | |||||
EV-to-EBITDA | -0.38 | |||||
EV-to-Revenue | 0.41 | |||||
EV-to-Forward-Revenue | 0.01 | |||||
EV-to-FCF | -0.37 | |||||
Price-to-GF-Value | 1.57 | |||||
| Price-to-Net-Current-Asset-Value | 1.01 | |||||
| Price-to-Net-Cash | 1.6 | |||||
Earnings Yield (Greenblatt) % | -285.71 | |||||
FCF Yield % | -99.08 |
InMed Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InMed Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-02-11 | In 167 days | ||
| General meeting for 2026 | 2026-12-17 16:00 | In 112 days | ||
| First quarter earnings results for 2027 | 2026-11-06 | In 70 days | ||
| Annual report for 2026 | 2026-09-23 | In 26 days | ||
| Fourth quarter earnings results for 2026 | 2026-09-23 | In 26 days | ||
| Third quarter earnings results for 2026 | 2026-05-06 | 0.74 (+0.91%) | ||
| Second quarter earnings results for 2026 | 2026-02-11 | 1.00 (+5.26%) | ||
| General meeting for 2025 | 2025-12-17 16:00 | 1.32 (-0.38%) | ||
| First quarter earnings results for 2026 | 2025-11-06 | 1.73 (+0.00%) | ||
| Annual report for 2025 | 2025-09-23 | 2.27 (+1.34%) |
Show
Entries
Press Release
Articles on InMed Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers